(PCVX) Vaxcyte - Ratings and Ratios
Pneumonia Vaccine, Strep Vaccine, Gum Disease Protein, Shigellosis Vaccine
PCVX EPS (Earnings per Share)
PCVX Revenue
Description: PCVX Vaxcyte
Vaxcyte Inc. is a clinical-stage vaccine innovation company focused on developing conjugate and novel protein vaccines to combat bacterial infectious diseases. Its primary vaccine candidates include VAX-24 and VAX-31, both designed to prevent invasive pneumococcal disease (IPD) in various age groups, and other candidates targeting diseases caused by Group A Streptococcus, periodontitis, and Shigella bacteria.
From a business perspective, key performance indicators (KPIs) to monitor Vaxcytes progress include the advancement of its vaccine candidates through clinical trials, partnerships or collaborations with larger pharmaceutical companies, and the potential for future revenue streams through successful vaccine launches. The companys ability to secure funding to support its research and development activities is also crucial, given its current negative return on equity (RoE) of -17.12%.
Investors should also keep an eye on the competitive landscape of the pneumococcal conjugate vaccine (PCV) market, where established players like Pfizer and Merck operate. Vaxcytes carrier-sparing technology and broad-spectrum coverage could be key differentiators. Additionally, the companys pipeline diversification across multiple vaccine candidates and disease targets may mitigate risks associated with any single product.
From a financial perspective, Vaxcytes market capitalization stands at approximately $4.82 billion, indicating a significant investor interest in the companys prospects. The absence of a price-to-earnings (P/E) ratio is expected given the companys stage of development and lack of profitability. As Vaxcyte progresses through clinical trials and potentially towards commercialization, investors will be watching closely for signs of future earnings growth and the companys ability to achieve profitability.
PCVX Stock Overview
| Market Cap in USD | 4,097m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2020-06-12 |
PCVX Stock Ratings
| Growth Rating | -12.0% |
| Fundamental | 18.6% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -76.2% |
| Analyst Rating | 4.90 of 5 |
PCVX Dividends
Currently no dividends paidPCVX Growth Ratios
| Growth Correlation 3m | -54.9% |
| Growth Correlation 12m | -88.8% |
| Growth Correlation 5y | 67.1% |
| CAGR 5y | 7.25% |
| CAGR/Max DD 3y | 0.10 |
| CAGR/Mean DD 3y | 0.70 |
| Sharpe Ratio 12m | -0.59 |
| Alpha | -92.22 |
| Beta | 0.919 |
| Volatility | 47.28% |
| Current Volume | 1465.4k |
| Average Volume 20d | 1375.5k |
| Stop Loss | 30.5 (-5.2%) |
| Signal | 0.12 |
Piotroski VR‑10 (Strict, 0-10) 2.0
| Net Income (-547.5m TTM) > 0 and > 6% of Revenue (6% = -32.3m TTM) |
| FCFTA -0.14 (>2.0%) and ΔFCFTA 3.10pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue -290.2% (prev 9682 %; Δ -9972 pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.14 (>3.0%) and CFO -459.5m > Net Income -547.5m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 11.11 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (136.0m) change vs 12m ago 16.01% (target <= -2.0% for YES) |
| Gross Margin 101.8% (prev 16.95%; Δ 84.81pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover -19.95% (prev 0.69%; Δ -20.65pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| error: Interest Coverage Ratio cannot be calculated (needs EBITDA TTM and Interest Expense TTM) |
Altman Z'' -7.56
| (A) 0.47 = (Total Current Assets 1.72b - Total Current Liabilities 154.5m) / Total Assets 3.31b |
| (B) -0.51 = Retained Earnings (Balance) -1.70b / Total Assets 3.31b |
| (C) -0.20 = EBIT TTM -549.1m / Avg Total Assets 2.70b |
| (D) -7.25 = Book Value of Equity -1.70b / Total Liabilities 234.0m |
| Total Rating: -7.56 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 18.55
| 1. Piotroski 2.0pt = -3.0 |
| 2. FCF Yield -18.84% = -5.0 |
| 3. FCF Margin -88.30% = -7.50 |
| 4. Debt/Equity 0.03 = 2.50 |
| 5. Debt/Ebitda -0.16 = -2.50 |
| 6. ROIC - WACC -26.11% = -12.50 |
| 7. RoE -16.85% = -2.50 |
| 8. Rev. Trend -4.37% = -0.22 |
| 9. Rev. CAGR 0.0% = 0.0 |
| 10. EPS Trend -29.19% = -0.73 |
| 11. EPS CAGR 0.0% = 0.0 |
What is the price of PCVX shares?
Over the past week, the price has changed by -0.74%, over one month by +2.35%, over three months by -6.29% and over the past year by -71.84%.
Is Vaxcyte a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of PCVX is around 24.60 USD . This means that PCVX is currently overvalued and has a potential downside of -23.53%.
Is PCVX a buy, sell or hold?
- Strong Buy: 9
- Buy: 1
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the PCVX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 114.9 | 257.1% |
| Analysts Target Price | 114.9 | 257.1% |
| ValueRay Target Price | 27.6 | -14.2% |
Last update: 2025-09-04 04:45
PCVX Fundamental Data Overview
CCE Cash And Equivalents = 1.66b USD (Cash And Short Term Investments, last quarter)
Revenue TTM is 0, using Net Income TTM -547.5m + Cost of Revenue 9.49m = -538.0m USD
P/B = 1.3015
Beta = 1.212
Revenue TTM = -538.0m USD
EBIT TTM = -549.1m USD
EBITDA TTM = -530.0m USD
Long Term Debt = 79.5m USD (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 6.30m USD (from shortTermDebt, last quarter)
Debt = 85.8m USD (Calculated: Short Term 6.30m + Long Term 79.5m)
Net Debt = -220.9m USD (from netDebt column, last quarter)
Enterprise Value = 2.52b USD (4.10b + Debt 85.8m - CCE 1.66b)
Interest Coverage Ratio = unknown (Ebit TTM -549.1m / Interest Expense TTM 0.0)
FCF Yield = -18.84% (FCF TTM -475.1m / Enterprise Value 2.52b)
FCF Margin = -88.30% (FCF TTM -475.1m / Revenue TTM -538.0m)
Net Margin = -101.8% (Net Income TTM -547.5m / Revenue TTM -538.0m)
Gross Margin = -101.8% ((Revenue TTM -538.0m - Cost of Revenue TTM 9.49m) / Revenue TTM)
Tobins Q-Ratio = -1.49 (set to none) (Enterprise Value 2.52b / Book Value Of Equity -1.70b)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 85.8m)
Taxrate = 21.0% (US default)
NOPAT = -549.1m (EBIT -549.1m, no tax applied on loss)
Current Ratio = 11.11 (Total Current Assets 1.72b / Total Current Liabilities 154.5m)
Debt / Equity = 0.03 (Debt 85.8m / last Quarter total Stockholder Equity 3.07b)
Debt / EBITDA = -0.16 (Net Debt -220.9m / EBITDA -530.0m)
Debt / FCF = -0.18 (Debt 85.8m / FCF TTM -475.1m)
Total Stockholder Equity = 3.25b (last 4 quarters mean)
RoA = -16.56% (Net Income -547.5m, Total Assets 3.31b )
RoE = -16.85% (Net Income TTM -547.5m / Total Stockholder Equity 3.25b)
RoCE = -16.50% (Ebit -549.1m / (Equity 3.25b + L.T.Debt 79.5m))
RoIC = -16.90% (NOPAT -549.1m / Invested Capital 3.25b)
WACC = 9.21% (E(4.10b)/V(4.18b) * Re(9.40%)) + (D(85.8m)/V(4.18b) * Rd(0.0%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 96.97 | Cagr: 7.41%
Discount Rate = 9.40% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow -475.1m)
Revenue Correlation: -4.37 | Revenue CAGR: 0.0%
Rev Growth-of-Growth: -1600
EPS Correlation: -29.19 | EPS CAGR: 0.0%
EPS Growth-of-Growth: 15.44
Additional Sources for PCVX Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle